Vertex Pharmaceuticals Incorporated
Computation of Ratio of Earnings to Fixed Charges
(Amounts in thousands)
| | 2003 | 2004 | 2005 | 2006 | 2007 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Loss from continuing operations before cumulative effect of a change in accounting principle | $ | (266,413 | ) | $ | (166,247 | ) | $ | (203,417 | ) | $ | (207,937 | ) | $ | (391,279 | ) | |
Fixed Charges: | ||||||||||||||||
| Interest expense and amortization of deferred issuance costs | 17,298 | 18,317 | 17,326 | 7,955 | 2,285 | |||||||||||
| Appropriate rental obligations | 8,204 | 11,963 | 11,164 | 12,074 | 10,243 | |||||||||||
| Total fixed charges | $ | 25,502 | $ | 30,280 | $ | 28,490 | $ | 20,029 | $ | 12,528 | ||||||
Loss from continuing operations before cumulative effect of a change in accounting principle, plus fixed charges | $ | (240,911 | ) | $ | (135,967 | ) | $ | (174,927 | ) | $ | (187,908 | ) | $ | (378,751 | ) | |
Ratio of earnings to fixed charges | * | * | * | * | * | |||||||||||
